A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age
Authors
Keywords
Clinical trial, Lot consistency, Immunogenicity and safety, Streptococcus pneumoniae, 20-valent pneumococcal conjugate vaccine
Journal
VACCINE
Volume 39, Issue 38, Pages 5428-5435
Publisher
Elsevier BV
Online
2021-07-25
DOI
10.1016/j.vaccine.2021.07.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
- (2020) Donald Hurley et al. CLINICAL INFECTIOUS DISEASES
- Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era
- (2020) Sara de Miguel et al. CLINICAL INFECTIOUS DISEASES
- Invasive pneumococcal disease in relation to vaccine type serotypes
- (2019) Paeton L. Wantuch et al. Human Vaccines & Immunotherapeutics
- Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia
- (2019) Raul E. Isturiz et al. VACCINE
- Limited indirect effects of an infant pneumococcal vaccination program in an aging population
- (2019) Mark van der Linden et al. PLoS One
- Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults
- (2019) Allison Thompson et al. VACCINE
- Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries
- (2018) Rachid Y. Yahiaoui et al. BMC INFECTIOUS DISEASES
- Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world
- (2017) Yadong A. Cui et al. Human Vaccines & Immunotherapeutics
- Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis
- (2017) Evelyn Balsells et al. PLoS One
- Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine
- (2016) Sara Tomczyk et al. CLINICAL INFECTIOUS DISEASES
- Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older
- (2016) Robert W. Frenck et al. VACCINE
- Interim results of an ecological experiment — Conjugate vaccination against the pneumococcus and serotype replacement
- (2016) William P Hausdorff et al. Human Vaccines & Immunotherapeutics
- Pneumococcal Capsules and Their Types: Past, Present, and Future
- (2015) K. Aaron Geno et al. CLINICAL MICROBIOLOGY REVIEWS
- Pneumococcal conjugate vaccine use in adults
- (2015) Raul E. Isturiz et al. Expert Review of Vaccines
- Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
- (2015) Matthew R Moore et al. LANCET INFECTIOUS DISEASES
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
- (2015) Marc J.M. Bonten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines
- (2015) Tamara Pilishvili et al. VACCINE
- Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
- (2015) Mark van der Linden et al. PLoS One
- Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality
- (2014) Zitta Barrella Harboe et al. CLINICAL INFECTIOUS DISEASES
- Pneumococcal infection in adults: burden of disease
- (2013) J.J.C. Drijkoningen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
- (2013) Lisa A. Jackson et al. VACCINE
- Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway
- (2013) Anneke Steens et al. VACCINE
- Understanding the burden of pneumococcal disease in adults
- (2012) F. Blasi et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells
- (2012) Elizabeth A. Clutterbuck et al. JOURNAL OF INFECTIOUS DISEASES
- The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
- (2011) David Cooper et al. VACCINE
- Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
- (2011) Elizabeth Miller et al. VACCINE
- Preparation of bacterial polysaccharide–protein conjugates: Analytical and manufacturing challenges
- (2009) Carl E. Frasch VACCINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started